Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer | Zendy

Neal D. Shore | Zendy; Raluca IonescuIttu | Zendy; Lingfeng Yang | Zendy; François Laliberté | Zendy; Malena Mahendran | Zendy; Dominique Lejeune | Zendy; Louise Yu | Zendy; Joseph E. Burgents | Zendy; Mei Sheng Duh | Zendy; Sameer R. Ghate | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Neal D. Shore,

Raluca IonescuIttu,

Lingfeng Yang,

François Laliberté,

Malena Mahendran,

Dominique Lejeune,

Louise Yu,

Joseph E. Burgents,

Mei Sheng Duh,

Sameer R. Ghate

Publication year - 2021

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-0153

Subject(s) - medicine , fanca , palb2 , prostate cancer , oncology , genetic testing , cancer , dna repair , gene , mutation , fanconi anemia , genetics , germline mutation , biology

Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research